Despite the UK’s world class research output and the many start-ups successfully spinning out from its academic institutions, in recent years UK biotech companies have struggled to access t
Alnylam’s European head of market access and GM of mid-size markets, Anant Murthy, shares his perspective on how a US biotech can adapt to the many unique challenges of the EU market.
More than 20 pharma companies including GlaxoSmithKline, Novartis and Pfizer have joined forces to create a $1 billion fund to save the pipeline of antibiotics drugs, after several biotechs
